Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets
WO42178
Quick answer
Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets for Persistent or Recurrent Rare Epithelial Ovarian Tumors is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active